Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enGene TherapeuticsENGN +1.78%12 OCF Yield % is -95.47 as of Aug. 18, 2026. GuruFocus rates ENGN with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, enGene Therapeutics ranks worse than 89.86% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
enGene Therapeutics OCF Yield % Related Terms
enGene Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for enGene Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, enGene Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where enGene Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Therapeutics (ENGN) has a OCF Yield % of -95.47 as of Aug. 18, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on enGene Therapeutics and its competitors. According to the industry distribution chart, enGene Therapeutics ranks #1267 out of 1410 companies in the Biotechnology industry, placing it in the top 89.9%.
Is enGene Therapeutics' OCF Yield % too high?
enGene Therapeutics' current OCF Yield % is -95.47. Based on the distribution chart, enGene Therapeutics ranks #1267 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, enGene Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' OCF Yield % compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #1267 out of 1410 companies for OCF Yield %. This places enGene Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on enGene Therapeutics and its competitors. enGene Therapeutics's current OCF Yield % is -95.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (ENGN) has a current OCF Yield % of -95.47. The current OCF Yield % is -95.47. enGene Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For enGene Therapeutics (ENGN), the current OCF Yield % is -95.47 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
12GF Score
Get the complete analysis for ENGN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENGN has been successfully added to your 
